|
Clinicopathologic variable
|
Mean (SD)/ Frequency (%) n = 4049
|
|---|
|
Age, in years
|
|
Mean, SD
|
57.6 (11.9)
|
|
< 65 years
|
2722 (67.2%)
|
|
≥ 65 years
|
1327 (32.8%)
|
|
Sex
|
|
Male
|
2694 (66.5%)
|
|
Female
|
1355 (33.5%)
|
|
BMI, in kg/m2
|
23.7 (3.1)
|
|
ASA
|
|
I
|
1540 (38.0%)
|
|
I
|
1991 (49.2%)
|
|
III
|
187 (4.6%)
|
|
Unknown
|
331 (8.2%)
|
|
pT size, in cm
|
4.6 (2.8)
|
|
pT category
|
|
T1
|
2049 (50.6%)
|
|
T2
|
595 (14.7%)
|
|
T3
|
787 (19.4%)
|
|
T4
|
618 (15.3%)
|
|
pN category
|
|
N0
|
2465 (60.9%)
|
|
N1
|
550 (13.6%)
|
|
N2
|
440 (10.9%)
|
|
N3
|
594 (14.7%)
|
|
Total number of pathologically positive lymph nodes
|
2.8 (6.3)
|
|
Total number of lymph nodes examined
|
|
Mean, SD
|
42.9 (15.9)
|
|
0–30
|
889 (22.0%)
|
|
31–45
|
1597 (39.4%)
|
|
> 45
|
1563 (38.6%)
|
|
pStage
|
|
IA
|
1815 (44.8%)
|
|
IB
|
501 (12.4%)
|
|
IIA
|
423 (10.4%)
|
|
IIB
|
330 (8.2%)
|
|
IIIA
|
303 (7.5%)
|
|
IIIB
|
341 (8.4%)
|
|
IIIC
|
336 (8.3%)
|
|
Tumor location
|
|
Proximal
|
683 (16.9%)
|
|
Middle
|
1370 (33.8%)
|
|
Distal
|
1916 (47.3%)
|
|
Whole
|
80 (2.0%)
|
|
Histologic gradea
|
|
Differentiated
|
1542 (38.1%)
|
|
Undifferentiated
|
2456 (60.7%)
|
|
Others
|
49 (1.2%)
|
|
Unknown
|
2 (0.05%)
|
|
Borrmann type
|
|
0
|
2214 (54.7%)
|
|
I
|
51 (1.3%)
|
|
II
|
374 (9.2%)
|
|
III
|
1269 (31.3%)
|
|
IV
|
121 (3.0%)
|
|
V
|
19 (0.5%)
|
|
Unknown
|
1 (0.02%)
|
|
Lauren type
|
|
Intestinal
|
1899 (46.9%)
|
|
Diffuse
|
1644 (40.6%)
|
|
Mixed
|
359 (8.9%)
|
|
Indeterminate/Unknown
|
147 (3.6%)
|
|
Lymphovascular invasion
|
|
Present
|
1596 (39.4%)
|
|
Absent
|
2340 (57.8%)
|
|
Unknown
|
113 (2.8%)
|
|
Perineural invasion
|
|
Present
|
948 (23.4%)
|
|
Absent
|
2293 (56.6%)
|
|
Unknown
|
808 (20.0%)
|
|
Resection type
|
|
Subtotal
|
2892 (71.4%)
|
|
Total
|
988 (24.4%)
|
|
Extended
|
169 (4.2%)
|
|
Extent of lymph node dissection
|
|
D1
|
126 (3.1%)
|
|
D2
|
3867 (95.5%)
|
|
> D2
|
46 (1.1%)
|
|
Unknown
|
10 (0.2%)
|
|
Adjuvant chemotherapyb
|
|
Yes
|
1002 (24.7%)
|
|
No
|
3012 (74.4%)
|
|
Unknown
|
35 (0.9%)
|
- Abbreviations: BMI body mass index, ASA American Society of Anesthesiology, pT pathologic tumor, pN pathologic nodal status
- aDifferentiated histology included papillary adenocarcinoma, well-differentiated tubular adenocarcinoma, and moderately differentiated adenocarcinoma. Undifferentiated histology included poorly differentiated adenocarcinoma, signet ring cell adenocarcinoma, and mucinous carcinoma. Others included adenosquamous, squamous, neuroendocrine, etc
- bAdjuvant chemotherapy was indicated in patients with Stage II disease and higher. Adjuvant chemotherapy after publication of S1 adjuvant therapy trial and initiation and subsequent publication of adjuvant capecitabine + oxaliplatin (XELOX) trial were either of the two. Prior to these trials, 5-fluorouracil-based chemotherapy was used
